Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared ESMO’s post on X, adding:
“Such a delight to join the ESMO Ambassadors and contribute to the latest and greatest to coverage of groundbreaking research at ESMO26.
Looking forward highlight advances in Precision Oncology, Tumor Agnostic approaches, + novel biomarkers advancing care for patients with rare cancers and much much more OncoAlert.”
Quoting ESMO’s post:
“ESMO is pleased to announce the ESMO Ambassadors for ESMO26.
They will share scientific highlights, expert perspectives and insights on the latest research presented at ESMO26 across tumor types and disciplines.
You can also read:
ESMO Introduces 34 Social Media Ambassadors for ESMO Congress 2026
